The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2(DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention and TAA binding fragments derived therefrom are of use for the diagnosis treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention vectors comprising these nucleic acids recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.